Pancreatic Cancer Research

ResearcherSapporo Medical UniversityActive in the last 2 years

Masayo Motoya

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2566-0382; OpenAlex author ID A5042948477. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
62
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 3 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 11

  1. Role of preoperative circulating tumor DNA in predicting occult metastases in resectable and borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.3748/wjg.v31.i32.109383↗
  2. Concordance of the histological diagnosis of type 1 autoimmune pancreatitis and its distinction from pancreatic ductal adenocarcinoma with endoscopic ultrasoun… Co-author DOI 10.1007/s00428-021-03236-w↗
  3. HOPS-R01 phase II trial evaluating neoadjuvant S-1 therapy for resectable pancreatic adenocarcinoma. Co-author DOI 10.1038/s41598-022-14094-0↗
  4. Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer. Co-author DOI 10.3390/ijms231911521↗
  5. FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study. Co-author DOI 10.1007/s00280-020-04206-w↗
  6. Amplification of mutant KRAS G12D in a patient with advanced metastatic pancreatic adenocarcinoma detected by liquid biopsy: A case report. Last author DOI 10.3892/mco.2021.2334↗
  7. Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovaria… Co-author DOI 10.1007/s10147-020-01721-x↗
  8. Clinical Outcomes of Biliary Drainage during a Neoadjuvant Therapy for Pancreatic Cancer: Metal versus Plastic Stents. Co-author DOI 10.5009/gnl18573↗
  9. Clinical usefulness of conversion surgery for unresectable pancreatic cancer diagnosed on multidetector computed tomography imaging: Results from a multicenter… Co-author DOI 10.1002/ags3.12272↗
  10. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderl… Co-author DOI 10.1016/j.ijrobp.2019.07.004↗
  11. MicroRNA-196b is an independent prognostic biomarker in patients with pancreatic cancer. Co-author DOI 10.1093/carcin/bgx013↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yasutoshi Kimura · 8 shared papers, 2017–2025 · strength 0.91
  2. Siew‐Kee Low · 3 shared papers, 2021–2025 · strength 0.50
  3. Satoshi Hirano · 5 shared papers, 2019–2022 · strength 0.48
  4. Masafumi Imamura · 3 shared papers, 2019–2025 · strength 0.38
  5. Toru Nakamura · 4 shared papers, 2019–2022 · strength 0.38
  6. Makoto Yoshida · 3 shared papers, 2019–2025 · strength 0.36
  7. Tsuyoshi Hayashi · 4 shared papers, 2019–2022 · strength 0.35
  8. Ichiro Takemasa · 3 shared papers, 2017–2025 · strength 0.34
  9. Kazunori Watanabe · 2 shared papers, 2022–2025 · strength 0.33
  10. Tõru Nakamura · 2 shared papers, 2022–2025 · strength 0.30
  11. Fabio Pittella-Silva · 2 shared papers, 2021–2022 · strength 0.29
  12. Yusuke Nakamura · 2 shared papers, 2021–2022 · strength 0.29
  13. Tomohiro Kubo · 1 shared paper, 2025 · strength 0.20
  14. Daisuke Kyuno · 1 shared paper, 2025 · strength 0.20
  15. Takeshi Murakami · 1 shared paper, 2025 · strength 0.20
  16. Nobumasa Mizuno · 2 shared papers, 2020–2021 · strength 0.19
  17. Masafumi Ikeda · 2 shared papers, 2020–2021 · strength 0.19
  18. Junji Furuse · 2 shared papers, 2020–2021 · strength 0.19
  19. Makoto Ueno · 2 shared papers, 2020–2021 · strength 0.19
  20. Chigusa Morizane · 2 shared papers, 2020–2021 · strength 0.19
  21. Masaki Kuwatani · 2 shared papers, 2019–2020 · strength 0.18
  22. Ikuhiro YAMADA · 1 shared paper, 2021 · strength 0.11
  23. Kumiko Umemoto · 1 shared paper, 2021 · strength 0.11
  24. Takeshi Terashima · 1 shared paper, 2021 · strength 0.11
  25. Yukio Yoshida · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.